The global cell therapy manufacturing market size accounted for USD 4.20 billion in 2023 and is predicted to grow around USD 16.89 billion by 2033, growing at a CAGR of 14.93% from 2024 to 2033.
Key Points
- The North America cell therapy manufacturing market size accounted for USD 1.85 billion in 2023 and is expected to attain around USD 7.43 billion by 2033.
- North America led the market with the major revenue share of 44% in 2023.
- Asia Pacific is expected to witness the fastest growth during the forecast period.
- By therapy type, the autologous cell therapy segment has held the biggest revenue share of 59% in 2023.
- By therapy type, the allogenic cell therapy segment is projected to be the fastest-growing segment over the forecast period.
- By technology type, the somatic cell technology segment held the largest share of the market in 2023.
- By technology type, the 3D technology segment is expected to grow at the fastest rate during the projected period.
- By source, the IPSC (induced pluripotent stem cell) segment dominated the market in 2023.
- By source, the bone marrow segment is the second largest segment in the global market.
- By application, the oncology segment has contributed the largest revenue share of 35% in 2023.
- By application, the neurological segment is projected to show fastest growth during the forecast period.
The cell therapy manufacturing market is a rapidly evolving sector within the biopharmaceutical industry, characterized by the production of therapeutic cells for the treatment of various diseases and conditions. This market encompasses a range of processes involved in the manufacturing, processing, and quality control of cell-based therapies, aiming to deliver safe and effective treatments to patients. Cell therapy holds significant promise for addressing unmet medical needs and has attracted substantial investment and research efforts worldwide.
Get a Sample: https://www.precedenceresearch.com/sample/4283
Growth Factors
Several key factors are driving the growth of the cell therapy manufacturing market. One primary factor is the increasing prevalence of chronic diseases such as cancer, cardiovascular disorders, and autoimmune conditions, which are driving the demand for innovative treatments like cell therapies. Additionally, advancements in biotechnology and regenerative medicine have spurred the development of novel cell-based therapies, further fueling market growth. Moreover, supportive regulatory frameworks and rising investments in research and development are facilitating the expansion of the cell therapy manufacturing landscape.
Region Insights:
The cell therapy manufacturing market exhibits varying dynamics across different regions. North America and Europe are leading regions, driven by established biotechnology hubs, strong regulatory frameworks, and significant investments in healthcare infrastructure. Asia-Pacific is emerging as a rapidly growing market, propelled by increasing healthcare expenditure, a large patient pool, and a growing focus on biotechnology and life sciences. Countries like China, Japan, and South Korea are particularly active in advancing cell therapy manufacturing capabilities.
Cell Therapy Manufacturing Market Scope
| Report Coverage | Details |
| Growth Rate from 2024 to 2033 | CAGR of 14.93% |
| Cell Therapy Manufacturing Market Size in 2023 | USD 4.20 Billion |
| Cell Therapy Manufacturing Market Size in 2024 | USD 4.83 Billion |
| Cell Therapy Manufacturing Market Size by 2033 | USD 16.89 Billion |
| Largest Market | North America |
| Base Year | 2023 |
| Forecast Period | 2024 to 2033 |
| Segments Covered | By Therapy Type, By Technology Type, By Source, and By Application |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Cell Therapy Manufacturing Market Dynamics
Drivers:
Several drivers contribute to the advancement of the cell therapy manufacturing market. Technological innovations in cell culture techniques, bioreactor systems, and automation are streamlining manufacturing processes and enhancing scalability. Collaborations between academic institutions, biotech firms, and pharmaceutical companies are fostering knowledge exchange and accelerating product development. Additionally, the growing adoption of personalized medicine approaches and the potential for off-the-shelf cell therapies are driving market expansion.
Opportunities:
The cell therapy manufacturing market presents significant opportunities for market participants. Expansion into emerging markets, especially in Asia-Pacific and Latin America, offers avenues for growth due to evolving regulatory landscapes and increasing healthcare investments. Furthermore, optimizing manufacturing processes to reduce costs and improve scalability is a key opportunity. Innovations in cryopreservation technologies and supply chain management are also poised to unlock new opportunities in the market.
Challenges:
Despite its immense potential, the cell therapy manufacturing market faces several challenges. One major challenge is the complexity and variability of cell-based products, necessitating stringent quality control measures and standardized manufacturing processes. Scalability remains a critical issue, particularly for autologous therapies that require customized manufacturing for each patient. Moreover, regulatory complexities and reimbursement uncertainties pose challenges for market adoption and commercialization of cell therapies. Addressing these challenges will be crucial for sustaining the growth and success of the cell therapy manufacturing market.
Read Also: Brazil Industrial Absorbent Market Size, Share, Report by 2033
Cell Therapy Manufacturing Market Recent Developments
- In March 2024, Cellars announced the completion of the first Cell Shuttle, an automated, cGMP-compliant cell therapy manufacturing platform to support the global demand for cell therapies while reducing the cost of manufacturing and process failure rates.
- In March 2023, Cell One Partners and the Center for Breakthrough Medicines (CBM) entered into a strategic collaboration aimed at accelerating the development and commercialization of cell and gene therapies. This collaboration brings together the expertise and resources of both organizations to drive innovation and advance the field of regenerative medicine.
- In September 2022, the Cell Therapy Manufacturing Center (CTMC) and Ori Bio collaborated to expedite the process development, commercialization, and clinical integration of cell therapies. This partnership aimed to enhance the advancement of cell-based treatments and bring them to patients more efficiently.
Cell Therapy Manufacturing Market Companies
- Merck KGaA
- Thermo Fisher Scientific
- Catalent, Inc
- Bio-Techne
- Cytiva
- Lonza
- The Discovery Labs
- Novartis AG
- Bristol-Myers Squibb Company
- Gilead Sciences, Inc.
Segments Covered in the Report
By Therapy Type
- Allogenic Cell Therapy
- Autologous Cell Therapy
By Technology Type
- Somatic Cell Technology
- Cell Immortalization Technology
- Viral Vector Technology
- Genome Editing Technology
- Cell Plasticity Technology
- 3D Technology
By Source
- IPSC (Induced Pluripotent Stem Cell)
- Bone Marrow
- Umbilical Cord
- Adipose Tissues
- Neural Stem
By Application
- Musculoskeletal
- Cardiovascular
- Gastrointestinal
- Neurological
- Oncology
- Dermatology
- Others
By Geography
- North America
- Asia Pacific
- Europe
- Latin America
- Middle East & Africa
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Web: https://www.precedenceresearch.com
Blog: https://www.expresswebwire.com/
Blog: https://www.uswebwire.com/
Blog: https://www.dailytechbulletin.com/
Blog: https://www.autoindustrybulletin.com/
